EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

Liver Cancer SUMMIT 2020

 

6-8 February 2020 Prague
Close
N. Poster
Poster title
Applicant name
Status
  P02-01 Treatment-related toxicity predicts for improved outcome in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitor therapy. David J. Pinato Received Received
  P07-01 Intratumoral EpCAM-positive cancer stem cell heterogeneity in patients with hepatocellular carcinoma and its impact on clinical outcome Johann von Felden Received Received
  P03-01 Tumor Burden Score: a useful tool to predict immune-related hepatotoxicity during immunotherapy in HCC Antonio DAlessio Received Received
  P06-01 Circulating microRNA-21 and microRNA-122: prognosis prediction and correlation with HIF-1alpha in hepatocellular carcinoma patients treated with transarterial chemoembolization Filippo Pelizzaro Received Received
  P01-01 Clinical Strategy of Diagnosing patients with Hepatocellular Carcinoma based on Latent Transforming Growth Factor-Beta Binding Protein 1 Mohamed Abdel-Samiee Received Received
  P04-01 Application of BCLC-B subclassification and the Hong Kong Liver Cancer Systems to Intermediate Stage Hepatocellular Carcinoma Coskun Ozer Demirtas Received Received
  P05-01 Hepatocellular Carcinoma in Non-Cirrhotic Liver Arises in a More Advanced Tumoral Appearance Coskun Ozer Demirtas Received Received
  P04-02 Curative versus palliative treatments for recurrent hepatocellular carcinoma: an italian nationwide study Francesca Carissimi Received Received
  P03-02 PIVKA-II is a useful biomarker for hepatocellular carcinoma in caucasian HCV cirrhotic patients treated with direct-acting antivirals Elisabetta Degasperi Received Received
  P06-02 Metabolic rewiring in tumoral primary cholangiocytes: perspective for target therapy Michela Anna Polidoro Received Received
  P02-02 Response rates to direct antiviral agents (DAA) among hepatitis C virus infected patients who develop hepatocellular carcinoma following DAA treatment Alessandro Croce Received Received
  P05-02 Global characterisation of tumor infiltrate of Intrahepatic Cholangiocarcinoma by Sigle-Cell Sequencing Ana Lleo Received Received
  P07-02 High rate of HBV S-integrated human ESPL1 fusion gene is detected in HBV-related liver cancer patients: A Chinese case-control study Rongming Wang Received Received
  OP01-02 Deleting in vivo beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or mesenchymal hepatoblastoma similaryto Apc loss-of-function Daniel Zaldumbide Received Received
  P01-02 Radiological and pathological characteristics associated with aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation marianne ziol Received Received
  P07-03 urinary epidermal growth factor-related transforming growth factors and serum alpha-fetoprotein as tumor markers of hepatocellular carcinoma Jung-Fa Tsai Received Received
  P02-03 Hepatotoxicity during treatment with immune checkpoint inhibitors: what happens to the liver with tumor infiltration? DAlessio Antonio Received Received
  P04-03 Association of single nucleotide polymorphisms for PNPLA3, Notch3 and EGF with hepatocellular carcinoma in alcohol-related liver disease Anna Mrzljak Received Received
  P01-03 Hepatocellular Carcinoma: Most common presentation and its association with Portal vein thrombosis in different age groups Muhammad Arsalan Received Received
  P03-03 External Validation of the Toronto Hepatocellular Carcinoma Risk Index in Turkish Cirrhotic Patients Coskun Ozer Demirtas Received Received
  P05-03 Filamin-A expression predicts recurrence of mass-forming cholangiocarcinoma after hepatectomy Flavio Milana Received Received
  P06-03 Circulating mir-4454 as a predictor of therapy response and disease-free survival in hepatocellular carcinoma Muhammad Yogi Pratama Received Received
  P03-04 Deletion of erk5 protein kinase in myeloid cells impairs liver regeneration in mice Giovanni Di Maira Received Received
  P07-04 Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinomas nathalie guedj Received Received
  P01-04 randomized, open label, perioperative phase 2 study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable hcc Ahmed Kaseb Received Received
  P02-04 Epidemiological trends of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease in Italy. On behalf of the ITA.LI.CA. study group Alessandro Vitale Received Received
  P06-04 Characterization of novel oncogenic and tumor suppressor circRNAs in hepatocellular carcinoma Rok Razpotnik Received Received
  P05-04 In vivo performance of PEG-coated gold nanoparticles mediated ultrasound guided radiofrequency ablation: a pilot study in swine Tudor Mocan Received Received
  P04-04 DKK1 drives cholangiocarcinoma growth through modulation of the immune microenvironment Ed Jarman Received Received
  P03-05 cfDNA in Hepatocellular Carcinoma Ksenia Ellum Received Received
  P06-05 Prognostic role of a new index (PECS index) in advanced biliary tract cancer patients treated with first line chemotherapy: Training and Validation cohorts. Giulia Rovesti Received Received
  P07-05 Clinical significance of serum albumin functional parameters for diagnosis of hepatocellular carcinoma Rinat Gimadiev Received Received
  P05-05 New prognostic score utilizing glypican-3 serum levels for the prediction of 6-month outcome after transarterial therapies for patients with intermediate stage hepatocellular carcinoma Anne Olbrich Received Received
  P04-05 Telomerase reverse transcriptase mutated circulating tumor DNA is a useful biomarker and predicts prognosis in Danish patients with hepatocellular carcinoma Stine Karlsen Received Received
  P01-05 Prognostication of hepatocellular carcinoma under Sorafenib: external validation of the PROSASH-II model Vito Sansone Received Received
  P02-05 Immunological approach to identify predictive factors for development of hepatocellular carcinoma in patients treated with direct-acting antivirals Zuzana MACEK JILKOVA Received Received
  P03-06 The impact of postoperative ascites on survival after hepatectomy for hepatocellular carcinoma: A multicentric nation-based analysis Simone Famularo Received Received
  P06-06 Hepatic lesion involvig the inferior vena cava: surgical management. Pio Corleone Received Received
  P02-06 Interplay of PNPLA3 and HSD17B13 variants in modulating the risk of hepatocellular carcinoma among hepatitis C virus infected patients Carla De Benedittis Received Received
  P01-06 Natural history of hepatobiliary hypointense-only found at magnetic resonance imaging with Gd-EOB-DTPA in cirrhotic patients: time-dependent effects of dimensional increase and diffusion weighted imaging alterations Francesca Benevento Received Received
  P05-06 Distinct mechanisms are responsible for the activation of the NRF2-KEAP1 pathway at different steps of hepatocarcinogenesis Amedeo Columbano Received Received
  P07-06 Salvage AALDLT for HCC beyond all criteria yield equivilant results to Milan criteria in high prevalence young HCC patients country. Manar Salah Received Received
  P04-06 Clinical outcome of lenvatinib therapy in Japanese patients with unresectable hepatocellular carcinoma a nationwide multicenter study Kaoru Tsuchiya Received Received
  P01-07 The concept of time-varying therapeutic hierarchy for patients with hepatocellular carcinoma: a multicenter cohort study. On behalf of the ITA.LI.CA. study group. Alessandro Vitale Received Received
  P03-07 Biochemical and Clinical Evidence of Hepatocellular Carcinoma among Poorly Viral Suppressed ART Initiators in Southwestern Nigeria Ayodeji Faremi Received Received
  P04-07 Umbelliferone loaded Nano-Lipidic Carrier exerts Diethylnitrosamine induced Hepatic Cancer via Attenuation of cellular inflammation and cell proliferation efl2yjk6bo efl2yjk6bo Received Received
  P06-07 Multicenter validation of a scoring system to predict survival in biliary tract cancers receiving second-line chemotherapy Massimiliano Salati Received Received
  P02-07 The NADPH oxidase NOX4 regulates lipid metabolism, which contributes to its tumor suppressor actions in hepatocellular carcinoma Isabel Fabregat Received Received
  P05-07 Prognostic role of blood eosinophil count in sorafenib-treated hepatocellular carcinoma patients: time to reconsider the minorities Giorgia Marisi Received Received
  P07-07 Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. David Pinato Received Received
  P03-08 Optimisation and qualification of tumour mutational burden (TMB) by targeted next-generation sequencing (tNGS) as a clinically applicable biomarker in hepatocellular carcinoma (HCC). David Pinato Received Received
  P04-08 Stereotactic ablative radiotherapy in the management of metastatic and recurrent biliary tract cancer: single institution analysis of outcome and toxicity. Ciro Franzese Received Received
  P06-08 The Six and Twelve score in a prospective cohort of patients with hepatocellular carcinoma treated with trans-arterial chemoembolization following a fixed schedule Marco Sanduzzi Zamparelli Received Received
  P02-08 Regorafenib improves survival after sorafenib treatment in patients with recurrent hepatocellular carcinoma after liver transplantation, compared to best supportive care Massimo Iavarone Received Received
  P05-08 Prevalence and impact of sarcopenia in patients undergoing liver transplantation for hepatocellular carcinoma Ana Ostojic Received Received
  P07-08 Possible hepatoprotective effect of chlorogenic acid and protocatechuic acid combinational approach against diethylnitrosamine induced hepatocarcinogenesis in rodents as a multitargeted ligand Ekta Yadav Received Received
  P01-08 Galactose Conjugated PPI Dendrimers for Liver targetting Mani Bhargava Received Received
  P05-09 Dissecting a novel strategy to target Mitochondria in Bile Duct Cancers Carotenuto Pietro Received Received
  P04-09 TREM2 protects the liver against hepatocellular carcinoma through multifactorial protective mechanisms Ibone Labiano Received Received
  P07-09 Patient-led functional genomics identifies novel drivers of intrahepatic cholangiocarcinoma Nicholas Younger Received Received
  P02-09 Nonalcoholic steatohepatitis is a risk factor for intrahepatic cholangiocarcinoma and affects its long-time outcome: results from a multicenter international case-control study Stefania De Lorenzo Received Received
  P01-09 Major impact of personalised dosimetry using 90Y loaded glass microspheres SIRT in HCC: final Overal Survival analysis of a multicentre randomized phase II study. Etienne Garin Received Received
  P06-09 Role of transient elastography in early detection of hepatocellular carcinoma in cirrhotic patients. Abdel Ghani Badran Received Received
  P03-09 Developing high drug-load arsenic trioxide microsphere for chemoembolization of hepatocellular carcinoma Gong Feng Received Received
  P07-10 NK-cell dysfunction in Hepatocellular Carcinoma: modulatory approches for functional restoration Alessandra Zecca Received Received
  P05-10 Epidemiology, features and outcome of patients transplanted for hepatocellular carcinoma in the last decade: a single center experience Federica Invernizzi Received Received
  P04-10 Novel protein biomarkers in serum extracellular vesicles for the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a mirror of the tumor features Ainhoa Lapitz Received Received
  P06-10 Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated HBV cirrhotics treated with NUC for 10 years Enrico Galmozzi Received Received
  P02-10 Albumin to gamma-glutamyltransferase and platelet to lymphocyte ratio do not predict recurrence and recurrence-free- survival after complete response to first-line HCC treatment Alberta De Monti Received Received
  P01-10 Liquid Crystalline Nanoparticles based delivery of an Anticancer bioactive Saurabh Bhargava Received Received
  P03-10 Evolution of indications for liver transplantation in the last 15 years: a single center experience in Madrid Christie Perello Received Received
  P03-11 Pilot study of transarterial radioembolization with Yttrium-90 in patients with hepatocellular carcinoma Pablo Florez-Díez Received Received
  P07-11 Safety Comparison between Drug-eluting Beads and Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: A Multicentre Study Lei Zhang Received Received
  P04-11 Does tumor size matter in intrahepatic cholangiocarcinoma? a population-based analysis Xianwei Yang Received Received
  P02-11 A Retrospective Analysis of the Course of LI-RADS 3-4 Hepatic Lesions Panita Mettikanont Received Received
  P01-11 Mitochondriotropic Carbon nanotubes for efficient Tumor Targetting Varun Bhargava Received Received
  P05-11 Autoimmunity associated with primary biliray cholangitis prevents the development of cholangiocarcinoma in mouse models Juliette Paillet Received Received
  P06-11 Circulating Small-RNA signature evidenced a susceptibility to HCC occurence in DAA-treated patients Devis Pascut Received Received
  P01-12 Hepatic Uptake Index in the hepatobiliary phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging estimates functional liver reserve and predicts post-hepatectomy liver failure Bruno Branciforte Received Received
  P07-12 The combination of EpCAM-positive circulating tumor cells and serum AFP/AFP-L3/DCP predicts outcome after curative resection of hepatocellular carcinoma Johann von Felden Received Received
  P03-12 Alpha Feta-Protein use as a standalone screening tool for hepatocellular carcinoma: single centre experience Clare Foley Received Received
  P02-12 Early recurrence of hepatocellular carcinoma after liver transplantation can be predicted by FDG-PET and microvascular invasion at explant pathology Federica Invernizzi Received Received
  P06-12 Therapy with DAA increases post-OLT survival but not the risk of recurrence in patients undergoing liver transplantation for HCV-related HCC Vito Sansone Received Received
  P05-12 Mitochondrial oxidative metabolism contributes to maintain a cancer stem cell phenotype in cholangiocarcinoma Mirella Pastore Received Received
  P04-12 c-Rel is a novel tumour suppressor and early prognostic indicator of hepatocellular carcinoma development jack leslie Received Received
  P05-13 Association between survival of patients with hepatocellular carcinoma and 18F-fluoro-2-deoxy-D-galactose positron emission tomography/computed tomography Kirstine Bak-Fredslund Received Received
  P04-13 Th therapeutic potential of adipose tissue-derived mesenchymal stem cells to enhance radiotherapy effects on hepatocellular carcinoma Lingyun Wu Received Received
  P01-13 DNA damage response protein checkpoint kinase 2 (CHK2) links chromosomal instability to cellular metabolism in hepatocellular carcinoma (HCC) Gianluca Bruno Received Received
  P06-13 Genetic risk factors of denovo hepatitis C-related hepatocellular carcinoma previously treated with direct acting antivirals hend shousha Received Received
  P07-13 Long-term prospective study of development of hepatocellular carcinoma in compensated cirrhosis Alessandra Pivetti Received Received
  P03-13 Feasibility of ultrasound-guided percutaneous biopsy in peri-hilar focal biliary lesions of the liver: a case series Roberto Gabbiadini Received Received
  P02-13 A genetic risk score predicts de novo hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct-acting antivirals Elisabetta Degasperi Received Received
  P01-14 Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma David Pinato Received Received
  P07-14 Characteristics of hepatocellular carcinoma post direct antiviral treatment of chronic hepatitis C patients : comparative study with non - direct - acting antivirals - treated patients Mohamed Fathey Abdelkhalek Elgazzar Received Received
  P02-14 Programmed Cell Death-1 Gene Haplotypes are Associated with Hepatocellular Carcinoma Coskun Ozer Demirtas Received Received
  P04-14 Serum lipidomic landscape of non-alcoholic fatty liver disease progression to hepatocellular carcinoma in a Caucasian population Monika Lewinska Received Received
  P03-14 Dysregulation of aquaporin-1 in human CCA cells triggers epithelial-mesenchymal transition CESAR GASPARI Received Received
  P05-14 Endothelial inducible T cell co-stimulator ligand (ICOSL) regulates adhesion molecule expression on liver endothelium: implications for senescence-mediated immune surveillance Daniel Patten Received Received
  P06-14 Analysis of risk factors for survival and recurrence of hepatocellular carcinoma after liver transplantation Petra Dinjar Kujundic Received Received
  P03-15 Tracking neutrophils within the hepatocellular carcinoma microenvironment - development of relevant orthotopic and ex-vivo 3D liver-HCC culture models Daniel Geh Received Received
  P06-15 Radiological response to trans-arterial chemoembolisation (TACE) determines outcome in patients with hepatocellular carcinoma (HCC) Nada Elamin Received Received
  P01-15 Prognostic significance of endocan and VEGF in the prediction of hepatocellular carcinoma in patients with compensated chronic viral hepatitis C-related cirrhosis Jolanta Zuwala-Jagiello Received Received
  P02-15 Hepatocellular carcinoma in co-infected patients: more aggressive tumor behavior? Lisa Rodrigues Da Cunha Saud Received Received
  P07-15 Common polymorphisms in the interleukin-1 beta gene are associated with HCV-related HCC in Caucasian patients Janett Fischer Received Received
  P05-15 Activated platelets drive carcinogenesis and tumor growth in hepatocellular carcinoma Natasa Pavlovic Received Received
  P04-15 Circulating levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of biliary tract cancer Sven Loosen Received Received
  P06-16 miR-34a is activated in NAFLD and NASH-associated HCC, and correlates with key disease hallmarks André Simão Received Received
  P02-16 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab (D) or durvalumab plus bevacizumab (B) therapy in patients (Pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-1 Humna Rizki Received Received
  P07-16 Incidence of indeterminate hepatic nodules in the preoperative magnetic resonance imaging in patients with colorectal cancer, their diagnosis, management and clinical outcome Mizelle Dsilva Received Received
  P03-16 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB) Leland Yee Received Received
  P04-16 Fatty acids regulate the biology of cholangiocarcinoma cells Giulia Lori Received Received
  P01-16 Developing a bio-mimetic 3D model for hepatocellular carcinoma and the stromal micro-environment Carlemi Calitz Received Received
  P05-16 Vascular invasion, portal vein thrombosis and dermatological events predict and prognosis the evolution and survival of patients with advanced hepatocellular carcinoma treated with sorafenib Ioana Riaño Received Received
  P02-17 A novel test and treat hepatitis C micro-elimination project among underserved communities in Islamabad, Pakistan Huma Qureshi Received Received
  P03-17 E2F1 and E2F2 regulate glycerophospholipid metabolism in nonalcoholic fatty-liver disease-related hepatocarcinogenesis Francisco Gonzalez-Romero Received Received
  P06-17 A novel significance of apurinic/apyrimidinic endonuclease/redox effector factor 1 protein in hepatic cancer stem cells Caecilia Sukowati Received Received
  P04-17 Role of the tandem SOX17-MRP3 in the poor response of cholangiocarcinoma to chemotherapy Elisa Lozano Received Received
  P07-17 Risk of developing hepatocellular carcinoma in patients with cirrhosis of viral etiology evaluated by the combination of alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II and glypican-3 Michela Ciruolo Received Received
  P01-17 Identification of a proteomic signature in advanced hepatocellular carcinoma predicting response to sorafenib Frederic Saltel Received Received
  P05-17 Hepatotoxicity from immune-checkpoint inhibition in the treatment of hepatocellular carcinoma: outcomes and tissue biomarker analysis Nicola Personeni Received Received
  P05-18 Serum metabolic biomarkers for the differential diagnosis of distal cholangiocarcinoma and pancreas ductal adenocarcinoma Ana Peleteiro Vigil Received Received
  P04-18 Comparison between stratification system for liver cancer BCLC and HKLC-5 as a predictor of mortality in a university hospital cohort in Chile Rodrigo Wolff Received Received
  P07-18 Composite targeting of nuclear receptors protects mice from NAFLD progression towards HCC Tawhidul Islam Received Received
  P06-18 Empowerment of liver cancer patients for an improved management of post-embolization syndrome: Impact of a Nurses Educational program Neus Llarch Received Received
  P01-18 The volume of enhancement of disease (VED) predicts the early response to treatment and overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib Claudia Campani Received Received
  P02-18 Regulation of the biology of cholangiocarcinoma (CCA) cells by extracellular-signal regulated kinase 5 (ERK5) Giovanni Di Maira Received Received
  P03-18 Surveillance improves survival of intrahepatic cholangiocarcinoma arisen in liver cirrhosis Pietro Guerra Received Received
  P05-19 SCCA-IgM predicts prognosis differently according to gender in hepatocellular carcinoma patients treated with transarterial chemoembolization Filippo Pelizzaro Received Received
  P02-19 A Blood-Based DNA Methylation Test for Early Detection of Hepatocellular Carcinoma Dhruvajyoti Roy Received Received
  P01-19 Development of diet-induced NASH/HCC model in Sprague Dawley rats. Lydie Carreres Received Received
  P06-19 SImBA: a user-friendly high throughput tool for spheroid invasion analysis of hepatocellular carcinoma cell lines Elias Van De Vijver Received Received
  P03-19 Inactivation of the BAP1 tumor suppressor defines a subgroup of hepatocellular carcinoma with fibrolamellar features Theo Hirsch Received Received
  P04-19 Magnetic resonance of hepatocellular carcinoma treated with radiofrequency ablation: Radiomics to predict treatment response - preliminary results Claudia Maccali Received Received
  P07-19 Variable expression of venous clot coordinator high mobility group box-1 in patients with hepatocellular carcinoma with or without portal vein thrombosis Erica Matino Received Received
  P03-20 Targeting antiapoptotic proteins Bcl-xL and Mcl-1 in cholangiocarcinoma Paula Katharina Morgane Hoffmeister Received Received
  P04-20 PARP-1 inhibition preferentially impairs KRAS-mutated intrahepatic cholangiocarcinoma and induces distinct molecular alterations Friederike Mahn Received Received
  P05-20 Differential Role of TGF-Beta1&2 on Proliferative and Invasive Properties in Primary Liver Cancer Sharon Pereira Received Received
  P02-20 miRNA profiling of biliary intraepithelial neoplasia reveals step-wise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis Stephanie Roessler Received Received
  P01-20 Portal hypertension and sequential bilobar treatment increase risk of hepatic decompensation in patients with hepatocellular carcinoma treated with 90Yttrium radioembolization Laura Carrion Received Received
  P06-20 Involvement of the glycan-binding protein galectin-1 in hepatocellular carcinoma cell drug resistance María Fernanda Troncoso Received Received
  P04-21 Inhibitory effects of butyrate carrier structured lipids on persistent preneoplastic lesions induced by the resistant hepatocyte model of hepatocarcinogenesis Juliana Marques Affonso Received Received
  PB07-21 SBRT vs TAE/TACE in Hepatocellular carcinoma: results from a Phase III trial (NTC02323360) Tiziana Comito Received Received
  P07-21 Advances in serum biomarkers for primary and secondary liver carcinomas Marie Karlikova Received Received
  P03-21 Protective role of aspirin chronic assumption in patients treated with sorafenib for hepatocellular carcinoma Luca Ielasi Received Received
  P02-21 plasma circulating cell-free DNA integrity is a risk factor of denovo hepatitis-C related hepatocellular carcinoma treated or not with direct acting antiviral therapy hend shousha Received Received
  P05-21 Critical modifications of ganglioside patterns in human cholangiocarcinoma Benedetta Piombanti Received Received
  P01-21 Targeting tumor-initiating cells as an effective approach to overcome sorafenib resistance in hepatocellular carcinoma Darko Castven Received Received
  P06-21 Transcriptome profiling of liver biopsies before antiviral treatment start can predict HCC development 8.3 years before clinical diagnosis in chronic Hepatitis B and C patients Stijn Van Hees Received Received
  P05-22 Applicability of Six and Twelve model in patients with hepatocellular carcinoma treated with DEB-TACE Maria Pipa Muñiz Received Received
  PB07-22 Inhibiting endoplasmic reticulum stress in hepatic stellate cells decreases the progression of hepatocellular carcinoma Natasa Pavlovic Received Received
  P02-22 The role of stereotactic body radiation therapy in the management of hepatocellular carcinoma: outcome and toxicity from a single institution experience. Ciro Franzese Received Received
  P06-22 ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and paracrine signalling between tumor cells and cancer-associated fibroblasts Javier Vaquero Received Received
  P01-22 Characterisation of a plasmid-based mouse model of liver cancer with concomitant liver injury Vincent Chiu Received Received
  P04-22 Application of serum cytokeratin-19 fragments (CYFRA 21-1) in predicting the prognosis of patients with hepatocellular carcinoma Michela Ciruolo Received Received
  P03-22 Impact of a Nurse Educational program for patients empowerment during sequential systemic therapy for hepatocellular carcinoma Gemma Iserte Fort Received Received
  PB04-23 Specific RNA profiles in serum and urine extracellular vesicles of patients with cholangiocarcinoma mimicking tumor tissue and cell expression: a novel liquid biopsy approach Ainhoa Lapitz Received Received
  PB07-23 Clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: subgroup analysis from the phase 3 CELESTIAL trial Jennifer Humbert Received Received
  PB05-23 miR-21 is increased in patients with NASH-associated HCC and contributes to hepatocarcinogenesis in mice with NAFLD Pedro Miguel Rodrigues Received Received
  P01-23 The role of endosonography and endosonography guided fine needle aspiration in detection of small sized liver metastasis in patients with pancreatic and gastro-intestinal malignancy Saeed M. El-Nahaas Received Received
  P02-23 Development of personalised human immunocompetent ex vivo models of primary and secondary liver cancers using precision cut tissue slice technology Ewald Doornebal Received Received
  PB03-23 Neoangiogenic transcriptomic signature identifies HCCs with worse response to treatment: long-term results of a prospective study Erica Villa Received Received
  PB05-24 Hepatic RIPK3 signalling differentially modulates lipid metabolism and inflammation/carcinogenesis in non-alcoholic steatohepatitis Marta B. Afonso Received Received
  PB07-24 Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab/placebo: results from two randomised phase 3 trials (REACH/REACH-2) Peter Galle Received Received
  PB03-24 Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer. John Connell Received Received
  PB04-24 Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides Julien Calderaro Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:30 Fri 8:30-15:00
12:32
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

Liver Cancer SUMMIT 2020

 

6-8 February 2020 Prague
HELP LINE
Manage Orders
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 06/02/2020 TO 06/02/2021
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                  
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 05/02/2020
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster




PosterSessionOnline
Logo Draft
 
Logo Cert